FDA goes on offense amid surge of criticism for recent drug decisions [CNN]
uniQure N.V. - Ordinary Shares (QURE)
Last uniqure n.v. - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
uniqure.com/investors-newsroom/overview.php
Company Research
Source: CNN
reporters Thursday to defend the agency's recent decision on an experimental medicine, calling it a “failed therapy” and railing against outside critics. The call focused on the FDA's decision to ask for an additional clinical trial from the biotechnology company UniQure before greenlighting it to apply for approval of its gene therapy for Huntington's disease, a fatal neurodegenerative disorder. Patients and the company had hoped the therapy could move into an FDA review based on existing evidence, a hope that was dashed Monday. But the regulator, who spoke on the condition of anonymity, also attacked outside scientists who serve on advisory committees for the agency, saying they “do not do their homework” and may be motivated by financial conflicts of interest. The official additionally singled out Dr. Janet Woodcock, a retired FDA veteran who called the UniQure decision “truly evil” in an interview with the New York Times this week. “Dr. Woodcock is an esteemed regulator,” th
Show less
Read more
Impact Snapshot
Event Time:
QURE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QURE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QURE alerts
High impacting uniQure N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
QURE
News
- FDA goes on offense amid surge of criticism for recent drug decisions [CNN]CNN
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QUREPR Newswire
- Holzer & Holzer, LLC Reminds QURE Investors of the April 13, 2026 Lead Plaintiff Deadline in the uniQure N.V. Securities Class ActionGlobeNewswire
- FDA official calls UniQure's Huntington's disease treatment a failure [Yahoo! Finance]Yahoo! Finance
- FDA official calls UniQure's gene therapy a ‘failed' treatment for Huntington's disease [CNBC]CNBC
QURE
Earnings
- 11/10/25 - Miss
QURE
Sec Filings
- 3/4/26 - Form 144
- 3/4/26 - Form 144
- 3/4/26 - Form 144
- QURE's page on the SEC website